ADVERSE DRUG REACTION REPORTING IN AYURVEDA: NATIONAL PHARMACOVIGILANCE FRAMEWORK AND REPORTING MECHANISM IN INDIA
Authors/Creators
- 1. Assistant Professor, Department of Kayachikitsa, Guru Nanak Ayurvedic Medical college and Research Institute, Gopalpur, Ludhiana, Punjab, India - 141118.
- 2. Assistant Professor, Department of Swasthavritta, Guru Nanak Ayurvedic Medical college and Research Institute, Gopalpur, Ludhiana, Punjab, India - 141118.
- 3. Professor, Department of Rog Nidan, Guru Nanak Ayurvedic Medical college and Research Institute, Gopalpur, Ludhiana, Punjab, India - 141118.
Description
Adverse Drug Reactions (ADRs) represent a significant challenge to patient safety across all systems of medicine, including Ayurveda. Despite the long-standing use of Ayurvedic medicines and their general perception as safe, adverse reactions have been increasingly reported due to factors such as inappropriate drug selection, improper dosage, prolonged use, drug–drug interactions, herbo-mineral formulations, and compromised drug quality. In response to these concerns, the Ministry of AYUSH, Government of India, established the Ayush Pharmacovigilance Program of India (APvPI) to systematically monitor and evaluate ADRs related to AYUSH medicines. This article aims to describe the concept of ADRs in Ayurveda, the importance of ADR reporting, the structured national pharmacovigilance framework, and the standardized reporting process followed in India. Strengthening ADR reporting practices among Ayurvedic practitioners is essential for enhancing drug safety, promoting rational drug use, and integrating Ayurveda into evidence-based healthcare systems.
Files
34 WJPSR 1909.pdf
Files
(852.6 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:c4aa78beb1c0cab6a23f9fcd218cbb9f
|
852.6 kB | Preview Download |
Additional details
References
- 1. The Importance of Pharmacovigilance, Compilation prepared by World Health Organization (WHO), Geneva, http://apps.who.int/medicinedocs/en/d/Js4893e/
- 2. Thatte U, Bhalerao S. Pharmacovigilance of Ayurvedic medicines. Indian J Pharmacol, 2008; 40(Suppl 1): S10–S12.
- 3. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet, 2000; 356: 1255–1259.
- 4. Patgiri BJ, et al. Safety evaluation and pharmacovigilance of Ayurvedic drugs. AYU, 2011; 32(3): 364–370.
- 5. WHO-UMC. The use of the WHO-UMC system for standardized case causality assessment.
- 6. Kumar A, et al. Challenges in pharmacovigilance of traditional medicines. J Ayurveda Integr Med, 2017; 8(2): 82–86.
- 7. Ayush Pharmacovigilance Program of India (APvPI), Compilation prepared by Ministry of AYUSH, Government of India, https://www.ayushsuraksha.com/
- 8. National Pharmacovigilance Centre for AYUSH medicines, All India Institute of Ayurveda (AIIA), New Delhi, https://www.aiia.gov.in/
- 9. Pharmacovigilance Network for AYUSH medicines, Central Council for Research in Ayurvedic Sciences (CCRAS), Ministry of AYUSH, Government of India, https://ccras.nic.in/
- 10. List of Peripheral Pharmacovigilance Centres in India, Ministry of AYUSH, Government of India, https://www.ayushsuraksha.com/
- 11. Causality Assessment of Suspected Adverse Drug Reactions, WHO–Uppsala Monitoring Centre (WHO-UMC), https://who-umc.org/